Hu HQ, Xin XY, Zhu YT, Fan RW, Zhang HL, Ye Y, Li D. Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics. World J Stem Cells 2024; 16(1): 1-6 [PMID: 38292439 DOI: 10.4252/wjsc.v16.i1.1]
Corresponding Author of This Article
Yang Ye, PhD, Assistant Professor, Department of Traditional Chinese Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. yeyang89@bjmu.edu.cn
Research Domain of This Article
Reproductive Biology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Jan 26, 2024; 16(1): 1-6 Published online Jan 26, 2024. doi: 10.4252/wjsc.v16.i1.1
Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics
Hang-Qi Hu, Xi-Yan Xin, Yu-Tian Zhu, Rui-Wen Fan, Hao-Lin Zhang, Yang Ye, Dong Li
Hang-Qi Hu, Xi-Yan Xin, Yu-Tian Zhu, Rui-Wen Fan, Hao-Lin Zhang, Yang Ye, Dong Li, Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing 100191, China
Co-corresponding authors: Yang Ye and Dong Li.
Author contributions: Hu HQ wrote the first draft of the manuscript; Xin XY, Zhu YT, Fan RW, and Zhang HL contributed to review and editing; Ye Y and Li D conceived, reviewed, and revised this paper. Ye Y and Li D contributed equally and share the corresponding authorship.
Supported bythe Cohort Construction Project of Peking University Third Hospital, No. BYSYDL2022013; Clinical Key Project of Peking University Third Hospital, No. BYSY2023049; Special Grant for Capital Health Research and Development, No. 2022-2-4097; and Funding from State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, No. BYSYSZKF2023027.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yang Ye, PhD, Assistant Professor, Department of Traditional Chinese Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. yeyang89@bjmu.edu.cn
Received: November 3, 2023 Peer-review started: November 3, 2023 First decision: December 5, 2023 Revised: December 9, 2023 Accepted: December 26, 2023 Article in press: December 26, 2023 Published online: January 26, 2024 Processing time: 79 Days and 17.5 Hours
Abstract
The incidence of premature ovarian insufficiency (POI) is increasing worldwide, particularly among younger women, posing a significant challenge to fertility. In addition to menopausal symptoms, POI leads to several complications that profoundly affect female reproductive function and overall health. Unfortunately, current clinical treatment strategies for this condition are limited and often yield unsatisfactory outcomes. These approaches typically involve hormone replacement therapy combined with psychological support. Recently, mesenchymal stem cell (MSC) therapies for POI have garnered considerable attention in global research. MSCs can restore ovarian reproductive and endocrine functions through diverse mechanisms, including controlling differentiation, promoting angiogenesis, regulating ovarian fibrosis, inhibiting apoptosis, enhancing autocrine and paracrine effects, suppressing inflammation, modulating the immune system, and genetic regulation. This editorial offers a succinct summary of the application of MSC therapy in the context of POI, providing evidence for groundbreaking medical approaches that have potential to enhance reproductive health and overall well-being for women.
Core Tip: Premature ovarian insufficiency (POI) is an increasing cause of infertility globally, particularly among younger women, with profound effects on reproductive function and health. With limited treatment options and unsatisfactory results, the use of mesenchymal stem cell (MSC) therapies offers promising transformative approaches to restore ovarian function and enhance reproductive health in women. This article provides a concise overview and evidence of the potential benefits of MSC therapy for POI.
